"Sustained-release preparations" are formulations designed for prolonged drug release to maintain enduring effectiveness, often through a first-order release rate.

Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).

A signal peptide is a short peptide (3-60 amino acids) that guides proteins to their designated cellular locations.

OBI Pharma announced the FDA has approved its investigational new drug application for OBI-992, allowing the start of a phase 1/2 clinical trial to evaluate their novel TROP2-targeted antibody-drug conjugate for cancer treatment.

AHR agonists are drugs that activate the aryl hydrocarbon receptor, used in treating various conditions like psoriasis and dermatitis.

Belief BioMed Group announced the start of patient treatment in a major BBM-H803 study. This gene therapy aims to treat hemophilia A and is independently developed by Belief BioMed.

Patent licenses are divided into the following five basic types.

Sciwind Biosciences Reveals Encouraging Preliminary Outcomes from a Final-Stage Study of Ecnoglutide (XW003), an Extended-Duration GLP-1 Mimetic with Selective cAMP Pathway Activation, in Chinese Adults Suffering from Type 2 Diabetes.

TPO receptor agonists are drugs that stimulate the thrombopoietin receptor, increasing platelet production.

Coherus BioSciences, Inc. has recently declared that their product, LOQTORZI™ (toripalimab-tpzi), can now be acquired from certain specialty distribution channels within the U.S. market.

When submitting an ANDA, generic drug manufacturers need to submit one of the following four statements in accordance with the provisions of the Orange Book.

Atom Bioscience, a biotech company specializing in innovative therapies for inflammation and metabolic diseases, announced FDA approval for the Phase 1 trial of its new drug, ABP-745.